Product Images Erzofri Extended-release

This text appears to be describing two prefilled syringes with different sizes: 22G x 12" and 23G x 1". The syringes come with Gray hub and Blue hub colors. Additionally, it mentions a hub and tip cap.*

This is a list of different drug interactions indicated by their enzyme mechanisms such as CYP2D6 inhibitor, CYP3A4 inducer, and Divalproex Sodium ER. The text also mentions terms like AUC and Cmax, which are related to drug absorption levels. Additionally, it includes a section about paliperidone Fold Change and 90% CI, showing changes relative to a reference drug without interactions.*

This text appears to compare renal and hepatic impairments with normal function, specifically looking at mild, moderate, and severe impairments. It also mentions age comparison (18-64 years old vs. >=65 years old) and analysis of area under the curve (AUC) as well as Cmax levels. Additionally, there is a reference to paliperidone fold change and 90% confidence interval in relation to a change relative to a reference.*

This text provides information on the estimated percent of subjects with relapse in a study comparing a placebo group (N=156) with a group receiving once-2-month paliperidone palmitate extended-release injectable suspension (N=156). The graph shows a timeline in days since randomization along with the corresponding percentages of subjects experiencing relapse.*

This data presents the estimated percentage of subjects experiencing treatment failure when using palmitate extended-release injectable suspension (N=226) compared to an oral antipsychotic (N=218) over a period of 450 days since randomization. The plot shows the values at different time points ranging from 120 days to 450 days, with 70% at the highest and 10% at the lowest for both treatments. This information can help in understanding the efficacy of once-a-month paliperidone for long-term treatment.*

Estimated Percent of Subjects with Relapse is provided for both the Placebo group and the Once-a-month Paliperidone Palmitate Extended-release Injectable Suspension group over a period of 420 days since randomization. The data compares the relapse rates between the two groups through a graph representing the percentage of subjects experiencing relapse over time.*

This text appears to be a medication label providing information on a drug called Erzofri in the form of an extended-release injectable suspension with a concentration of 39mg/0.25mL. The medication is for intramuscular injection and should only be administered by a healthcare professional. The label also includes instructions on usage, dosage, and the content of the kit, which contains prefilled syringes and needles. Additionally, it mentions some of the inactive ingredients in the medication.*

This is a description of a medication called Erzofri, which is an extended-release injectable suspension intended for single use only. Each pre-filled syringe contains 78 mg/0.5 mL of the active ingredient Paliperidone Palmitate. The kit includes 1 pre-filled syringe and 2 needles for administration. It is important to follow the instructions provided and to consult a healthcare professional before administration. The formulation contains various active and inactive ingredients necessary for the medication's effectiveness and stability.*

This is a description for the drug Erzof (paliperidone palmitate) 117 mg/0.75 mL extended-release injectable suspension. The medication is for intramuscular injection only and must be administered by a healthcare professional. The kit contains 1 prefilled syringe with 117 mg/0.75 mL and 2 needles for injection. It should not be mixed with other products. The recommended dosage can be found in the prescribing information. The inactive ingredients include citric acid monohydrate, dibasic sodium phosphate, polysorbate 20, and sodium hydroxide. Shake before using.*

Description: This is a prescription drug named "Erzofi 156 mg/mL," which contains paliperidone palmitate in an extended-release injectable suspension form. The drug is administered by healthcare professionals via injection. Each kit includes a prefilled syringe with the medication and needles for administration. The recommended dosage and instructions for use are provided on the packaging. The suspension also contains various inactive ingredients for the formulation.*

This text appears to be a medication label for an injectable suspension called Erzofrit containing 234 mg per 1.5 mL of paliperdone palmitate. It includes instructions for intramuscular injection, details on kit contents, recommended dosage, and storage instructions. The product is for single-use and must be administered by a healthcare professional. The label also lists inactive ingredients and proper handling guidelines.*

NDC 72526-110-11 wxonly 351mg/225mL is a type of extended-release injectable suspension for intramuscular injection only. Each injection must be administered by a healthcare professional. The product contains paliperidone palmitate as an active ingredient. It comes with prefilled syringes containing 225 mL volume and 2 needles. The dosage provided is 351mg/225 mL. It is recommended for intramuscular injection only. This item should be shaken before use. The product is for healthcare institutional use.*